331 related articles for article (PubMed ID: 32961040)
21. SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response.
Huang J; Hume AJ; Abo KM; Werder RB; Villacorta-Martin C; Alysandratos KD; Beermann ML; Simone-Roach C; Lindstrom-Vautrin J; Olejnik J; Suder EL; Bullitt E; Hinds A; Sharma A; Bosmann M; Wang R; Hawkins F; Burks EJ; Saeed M; Wilson AA; Mühlberger E; Kotton DN
Cell Stem Cell; 2020 Dec; 27(6):962-973.e7. PubMed ID: 32979316
[TBL] [Abstract][Full Text] [Related]
22. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
23. Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2.
Liang H; Zhao L; Gong X; Hu M; Wang H
Clin Transl Sci; 2021 May; 14(3):1123-1132. PubMed ID: 33606912
[TBL] [Abstract][Full Text] [Related]
24. Human Induced Pluripotent Stem Cell-Derived Lung Epithelial System for SARS-CoV-2 Infection Modeling and Its Potential in Drug Repurposing.
Surendran H; Nandakumar S; Pal R
Stem Cells Dev; 2020 Nov; 29(21):1365-1369. PubMed ID: 32867617
[TBL] [Abstract][Full Text] [Related]
25. Perspectives for repurposing drugs for the coronavirus disease 2019.
Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408
[TBL] [Abstract][Full Text] [Related]
26. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
27. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
28. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
Wang S; Sun Q; Xu Y; Pei J; Lai L
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
[TBL] [Abstract][Full Text] [Related]
29. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
30. Identification of potential pan-coronavirus therapies using a computational drug repurposing platform.
Hwang W; Han N
Methods; 2022 Jul; 203():214-225. PubMed ID: 34767922
[TBL] [Abstract][Full Text] [Related]
31. Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection.
Pei R; Feng J; Zhang Y; Sun H; Li L; Yang X; He J; Xiao S; Xiong J; Lin Y; Wen K; Zhou H; Chen J; Rong Z; Chen X
Protein Cell; 2021 Sep; 12(9):717-733. PubMed ID: 33314005
[TBL] [Abstract][Full Text] [Related]
32. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
33. Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19.
Das G; Das T; Chowdhury N; Chatterjee D; Bagchi A; Ghosh Z
Genomics; 2021 Jan; 113(1 Pt 2):1129-1140. PubMed ID: 33189776
[TBL] [Abstract][Full Text] [Related]
34. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
Akilesh SM; J R; Palanisamy D; Wadhwani A
Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
36. Application of artificial intelligence and machine learning in drug repurposing.
Ghandikota SK; Jegga AG
Prog Mol Biol Transl Sci; 2024; 205():171-211. PubMed ID: 38789178
[TBL] [Abstract][Full Text] [Related]
37.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
38. Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection?
Le Corre P; Loas G
J Clin Pharm Ther; 2021 Oct; 46(5):1213-1219. PubMed ID: 33645763
[TBL] [Abstract][Full Text] [Related]
39. Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection.
Loucera C; Esteban-Medina M; Rian K; Falco MM; Dopazo J; Peña-Chilet M
Signal Transduct Target Ther; 2020 Dec; 5(1):290. PubMed ID: 33311438
[No Abstract] [Full Text] [Related]
40. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
